In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating on Esperion Therapeutics ESPR, and raised the price target from $26.00 to $38.00.
In the report, Credit Suisse noted, “Study 008 clearly demonstrated the superior efficacy of ETC-1002 over Zetia and surprisingly strong data for the all oral combination ETC-1002 / Zetia. The safety profile was consistent with prior trials and more convincing with larger patient numbers, but long-term safety remains an open question. We are increasing our target to $38 from $26 with an increase to our probability of success to 60% from 55% in statin intolerant patients and to 45% from 33% in residual risk patients. Estimates increase on probability of success and forecast partnership.”
Esperion Therapeutics closed on Wednesday at $24.42.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in